Seeking Alpha

More on Pfizer (PFE -0.6%) Q3: net profit falls to $3.21B from $3.74B. Sales -16%, hurt by forex...

More on Pfizer (PFE -0.6%) Q3: net profit falls to $3.21B from $3.74B. Sales -16%, hurt by forex and weaker than expected sales of Prevnar vaccine and Lipitor, which lost patent protection. Sales from key medicines, including Enbrel, Celebrex and Lyrica, continue to grow. Narrows FY EPS estimate to $2.14-$2.17 on revenue of $58B-$59B, both below consensus. Authorizes $10B buyback on completion of sale of nutrition business.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|